E7016 / Eisai  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
E7016 / Eisai
NCT01605162: Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Terminated
2
8
US
TMZ, E7016
Eisai Inc.
Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma
02/14
02/14

Download Options